You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsing forms

Showing 1 - 25 of 4,106
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsing Forms of Multiple Sclerosis Trial (BIIB091, DRF, Placebo)

Not yet recruiting
  • Relapsing Forms of Multiple Sclerosis
  • (no location specified)
Mar 23, 2023

Multiple Sclerosis Trial (Frexalimab, Teriflunomide, Placebo infusion)

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Nov 15, 2023

Multiple Sclerosis Trial (Dimethyl fumarate)

Not yet recruiting
  • Multiple Sclerosis
  • Dimethyl fumarate
  • (no location specified)
Dec 12, 2022

Ocrelizumab and Ofatumumab Administration in Relapsing Multiple

Completed
  • Relapsing Forms of Multiple Sclerosis
  • Lutherville, Maryland
  • +1 more
Oct 19, 2022

Relapsing Forms of Multiple Sclerosis Trial in Australia, United States (EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD)

Recruiting
  • Relapsing Forms of Multiple Sclerosis
  • EHP-101 25 mg OD
  • +3 more
  • Cullman, Alabama
  • +3 more
Apr 29, 2022

Multiple Sclerosis Trial in Stockholm (temelimab 18 mg/kg, temelimab 36 mg/kg, temelimab 54 mg/kg)

Completed
  • Multiple Sclerosis
  • temelimab 18 mg/kg
  • +3 more
  • Stockholm, Sweden
    Center for Neurology, Academic Specialist Center
Jul 4, 2022

Multiple Sclerosis (MS) Trial in Dallas (Alemtuzumab)

Completed
Has Results
  • Multiple Sclerosis (MS)
  • Dallas, Texas
  • +1 more
Jan 24, 2022

Diroximel Fumarate Real-world Experience in Canada and Israel

Recruiting
  • Relapsing Forms of MS
  • Diroximel Fumarate
  • Haifa, Israel
  • +5 more
Jan 31, 2023

Relapsing Forms of Multiple Sclerosis Trial in China, Japan (Diroximel fumarate)

Recruiting
  • Relapsing Forms of Multiple Sclerosis
  • Diroximel fumarate
  • Tianjin, China
  • +23 more
Jul 22, 2022

Multiple Sclerosis Trial in Los Angeles (Blood draw for future biomarker analysis)

Completed
Has Results
  • Multiple Sclerosis
  • Blood draw for future biomarker analysis
  • Los Angeles, California
    Investigational Site Number 8400001
Mar 15, 2022

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Relapsing Remitting Multiple Sclerosis Trial in United States (Ublituximab)

Active, not recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Ublituximab
  • Pasadena, California
  • +7 more
Aug 19, 2022

Multiple Sclerosis Trial in Stockholm (Temelimab 18 mg/kg, Temelimab 36mg/kg, Temelimab 54 mg/kg)

Terminated
  • Multiple Sclerosis
  • Temelimab 18 mg/kg
  • +2 more
  • Stockholm, Sweden
    Center for Neurology, Academic Specialist Center
Jul 4, 2022

Relapsing Multiple Sclerosis Trial in Boston (Ofatumumab, [F-18]PBR06)

Recruiting
  • Relapsing Multiple Sclerosis
  • Boston, Massachusetts
    Partners MS Center, 60 Fenwood Road
Jul 20, 2021

Multiple Sclerosis, Relapsing-Remitting Trial in Canada, United States (23-PPV, 13-PCV Booster, Influenza Vaccine)

Completed
Has Results
  • Multiple Sclerosis, Relapsing-Remitting
  • 23-PPV
  • +5 more
  • Cullman, Alabama
  • +21 more
Apr 4, 2022

Relapsing Multiple Sclerosis Trial in Worldwide (Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib)

Recruiting
  • Relapsing Multiple Sclerosis
  • Beijin, China
    Peking University Third Hospital
Jul 6, 2021

Study of Diroximel Fumarate in the Real-World Setting

Recruiting
  • Relapsing Forms of MS
  • Diroximel Fumarate
  • Washington, District of Columbia
  • +11 more
May 9, 2022

Multiple Sclerosis Trial in United States (Ublituximab, Placebo)

Completed
Has Results
  • Multiple Sclerosis
  • Ublituximab
  • Placebo
  • Phoenix, Arizona
  • +11 more
Jun 22, 2021

Multiple Sclerosis Trial in Newark (Betaseron, Copaxone)

Completed
Has Results
  • Multiple Sclerosis
  • Newark, New Jersey
    New Jersey Medical School
Oct 18, 2021

Multiple Sclerosis, Relapsing-Remitting Trial in Verona, Lørenskog (GSK1223249, Saline )

Terminated
  • Multiple Sclerosis, Relapsing-Remitting
  • Verona, Veneto, Italy
  • +1 more
Nov 20, 2020

Multiple Sclerosis Trial in Aurora (Ocrelizumab, Rituximab)

Completed
Has Results
  • Multiple Sclerosis
  • Aurora, Colorado
    University of Colorado Hospital
Jul 1, 2021

Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis Trial

Active, not recruiting
  • Secondary Progressive Multiple Sclerosis
  • +2 more
  • Minneapolis, Minnesota
  • +2 more
Mar 29, 2022

Assess Resource Utilization and Quality of Life of RRMS Treated

Completed
  • RRMS
  • Dimethyl Fumarate (DMF)
  • Thessaloniki, Greece
    University General Hospital AHEPA (B')
Jul 27, 2021

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting Trial in Germany, United States (Tetanus, diphtheria, and acellular

Recruiting
  • Multiple Sclerosis
  • Multiple Sclerosis, Relapsing-Remitting
  • Tetanus, diphtheria, and acellular pertussis vaccine
  • +2 more
  • Palo Alto, California
  • +47 more
Jun 24, 2022

Relapsing Multiple Sclerosis (RMS) Trial in United States (Ublituximab, Teriflunomide, Oral Placebo)

Completed
Has Results
  • Relapsing Multiple Sclerosis (RMS)
  • Ublituximab
  • +3 more
  • Phoenix, Arizona
  • +12 more
Nov 11, 2021